Non-small Cell Lung Cancer
Conditions
Brief summary
This is a randomized, multicenter, open, controlled phase III trial. 388 subjects with stage IIIB who were not eligible for radical surgery or radiotherapy, stage IV or recurrent squamous cell NSCLC were enrolled in this study .The subjects will be randomly assigned to one of the two treatment groups at a 1: 1 ratio, and stratified by sex, ECOG physical status, smoking status, disease staging.
Detailed description
Subjects will receive one of two treatment regimens: Group A: intravenous infusion of paclitaxel (albumin binding) 260 mg/m2, intravenous infusion, carboplatin area under curve （AUC) = 6, intravenous infusion, starting from randomization, once every 3 weeks, for 4-6 cycles,or progression, or intolerance, or deth or start a new anti-tumor treatment, whichever occurs first. Group B: paclitaxel injection 175 mg/m2, intravenous infusion, carboplatin AUC= 6, intravenous infusion, starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.The primary end point is overall response rate (ORR),the secondary endpoint is progression-free survival (PFS), overall survival (OS), safety and Quality of Life (QOL).
Interventions
DRUGnab-paclitaxel
albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
DRUGPaclitaxel
paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
DRUGCarboplatin
carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Accepted the purpose of the trial, the contents , the predicted efficacy, pharmacological effects and the full explanation of the risk and was understood that the subject had signed the informed consent. * Subjects had histopathologically or cytologically confirmed NSCLC type of squamous cell carcinoma and were documented; (must be provided without radiotherapy, fixed with formalin, paraffin At least 5 sheets of tumor tissue after embedding) * Subjects were IIIB who were not suitable for radical surgery or radiotherapy, IV or recurrent NSCLC ; (according to the 7th edition of the International Lung Cancer Research Council (IASLC) classification) * Subjects who were palliative radiotherapy for bone lesions other than the chest were given the study drug according to CTCAE 4.03 toxicity ≤1 * at least one measurable objective lesions according to RECIST1.1 standard * ECOG score ≤ 1 * Expected survival time ≥ 3 months * Subjects are well-behaved, able to undergo treatment and follow-up, and voluntarily comply with this study * ≥ 18 years old male and female * The childbearing age subjects must agree to take effective contraceptive measures during the trial; the serum or urine pregnancy test must be negative before 24 hours of the start of chemotherapy * Women must be non-lactating
Exclusion criteria
* There is brain metastases; * The investigators believe that uncontrolled serious medical illnesses that affect the ability of subjects to receive research programs, such as severe medical illnesses, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, Uncontrolled infections, active peptic ulcers; * Will hinder the understanding or make informed consent or fill in the questionnaire of dementia, mental state changes or any mental illness; * Any history of allergic or hypersensitivity to any treatment ingredient; * In the first 5 years of randomization, there were malignant tumors other than NSCLC, except for the treatment of basal cells or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ * Previously received treatment for advanced/metastatic NSCLC. Note: Allow chemotherapy and radiotherapy to be used as part of neoadjuvant/adjuvant therapy as long as the treatment has ended at least 12 months before the diagnosis of advanced or metastatic disease. * Received a taxane-based regimen as a neoadjuvant/adjuvant therapy for squamous cell carcinoma ; * Subjects with ≥2 grade peripheral neuropathy according to CTCAE V 4.03; * Physical examination and laboratory test results are abnormal ANC：\<1.5×109 / L； PLT：\<100×109/L； Hb: \<90g/L * Abnormal liver function is defined as: I) total bilirubin (TBil) level:\> normal upper limit (ULN) 1.5 times; II) 2.5 times the rate of aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\> ULN, and\> 5 times ULN if liver metastases are present * Definition of renal dysfunction: Serum creatinine\> ULN 1.5 times, or creatinine clearance \<50ml/min * Coagulation function abnormal definition: International Standardization Ratio (INR)\> 1.5 times the ULN, and prothrombin time (PT) or activated partial coagulation Blood enzyme time (aPTT)\> ULN 1.5 times, unless the subject is receiving anticoagulant therapy * Hepatitis B surface antigen positive (HBsAg), and peripheral blood hepatitis B virus DNA (HBV-DNA) titer ≥ 1×103copy number / L of the subjects; if HBsAg positive, and peripheral blood HBV-DNA \<1 × 103 copy number / L, if the researchers believe that the subjects in a stable phase of chronic hepatitis B and does not increase the risk of subjects, the subjects eligible to be selected * Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV) antibody positive * need to merge other anti-tumor drug treatment * Received any other test drug treatment or participated in another interventional clinical trial before 30 days of screening period; * Researchers think it is not suitable for enrolling.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall respond rate | overall respond rate will be evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months. | the rate of CR and PR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months | progression free survival |
| os | From date of randomization until the date of death from any cause,assessed up to 18 months | overall survival |
| Quality of life assessment | It will be assessed before the administration of drugs at each first day of the chemotherapy cycle,up to 6 cycles,each cycle is 21 days. | evaluate the QOL according to Functional Assessment of Cancer Therapy-lung (FACT-L) |
Contacts
Primary Contactyumei wang, docter
Outcome results
None listed